Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development

Licensed L1-VLP-based immunizations against high-risk mucosal human papillomavirus (HPV) types have been a great success in reducing anogenital cancers, although they are limited in their cross-protection against HPV types not covered by the vaccine. Further, their utility in protection against cuta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmels, Melinda, Mariz, Filipe C., Braspenning-Wesch, Ilona, Stephan, Sonja, Huber, Bettina, Schmidt, Gabriele, Cao, Rui, Müller, Martin, Kirnbauer, Reinhard, Rösl, Frank, Hasche, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574214/
https://www.ncbi.nlm.nih.gov/pubmed/36263027
http://dx.doi.org/10.3389/fimmu.2022.1010790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574214/
https://www.ncbi.nlm.nih.gov/pubmed/36263027
http://dx.doi.org/10.3389/fimmu.2022.1010790

Ejemplares similares